Mukopolysaccharidose (MPS). Clinical and neuroradiological aspects of the different types

Clinical Neuroradiology

Volumn 17, Issue 3, 2007, Pages 141-158

  Müller Forell, Wibke ^a,b   Schulze Frenking, Gudrun ^a   Amraoui, Yasmina ^a   Beck, Michael ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Leukencephalopathy; MRI; Mucopolysaccharidosis (MPS); Myelopathy; Perivascular space

Indexed keywords

IDURONATE 2 SULFATASE; LEVO IDURONIDASE;

CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DURA MATER; ENZYME DEFECT; ENZYME REPLACEMENT; HISTOLOGY; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYDROCEPHALUS; LABORATORY TEST; LEUKOENCEPHALOPATHY; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; MENTAL DEFICIENCY; METABOLIC DISORDER; MORQUIO SYNDROME; MUCOPOLYSACCHARIDOSIS; MUCOPOLYSACCHARIDOSIS TYPE 7; NEUROIMAGING; NEURORADIOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; PREVALENCE; REVIEW; SANFILIPPO SYNDROME; SCHEIE SYNDROME; WHITE MATTER;

EID: 34547903894     PISSN: 09397116     EISSN: 16156706     Source Type: Journal    
DOI: 10.1007/s00062-007-7017-1     Document Type: Review

References (141)

1. Brante G. Gargoylism; a mucopolysaccharidosis. Scand J Clin Lab Invest 1952;4:43-6, cited by Van Hoof F. Mucopolysaccharidoses and mucolipidoses. J Clin Pathol Suppl (R Coll Pathol) 1974;8:64-93.
2. Meyer K, Grumbach MM, Linker A, Hoffman P. Excretion of sulfated mucopolysaccharides in gargoylism (Hurler's syndrome). Proc Soc Exp Biol Med. 1958;97:275-9.
3. McKusick VA, Kaplan D, Wise D, Hanley WB, Suddarth SB, Sevick ME, Maumanee AE. The genetic mucopolysaccharidoses. Medicine (Baltimore) 1965;44:445-83.
4. Van Hoof F. Mucopolysaccharidoses and mucolipidoses. J Clin Pathol Suppl (R Coll Pathol) 1974;8:64-93.
5. Heuer GG, Passini MA, Jiang K, Parente MK, Lee VM, Trojanowski JQ, Wolfe JH. Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol 2002;52:762-70.
6. Neufeld EF. Lysosomal storage diseases. Ann Rev Biochem 1991;60:257-80.
7. Brooks AI, Stein CS, Hughes SM, Heth J, McCray PM, Sauter SL, Johnston JC, Cory-Slechta DA, Federoff HJ, Davidson BL. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA. 2002;99:6216-21.
8. Lake B. Lysosomal and peroxisomal disorders. The mucopolysaccharidoses. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology, 6th ed. Arnold, London 1997, pp 657-753.
9. Akhtar S, Tullo A, Caterson B, Davies JR, Bennett K, Meek KM. Clinical and morphological features including expression of betaig-h3 and keratan sulphate proteoglycans in Maroteaux-Lamy syndrome type B and in normal cornea. Br J Ophthalmol 2002;86:147-51.
10. Van der Knaap MS, Valk J. Mucopolysaccharidoses. In: van der Knaap MS, Valk J, eds. Magnetic resonance of myelination and myelin disorders, 3rd ed. Springer Heidelberg-New York-Wien 2005, pp 123-32.
11. Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, Fuller M, Christensen E, Skovby F, Hopwood JJ. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics 2004;114:909-16.
12. Nelson J, Crowhurst J, Carey B, Greed L. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet A 2003;123:310-3.
13. Bähner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlschütter A, Kampmann C, Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005;28:1011-7.
14. Hopwood JJ, Bunge S, Morris CP, Wilson PJ, Steglich C, Beck M, Schwinger E, Gal A. Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hum Mutat 1993;2:435-42.
15. Bradford TM, Litjens T, Parkinson EJ, Hopwood JJ, Brooks DA. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): a Y210C mutation causes either altered protein handling or altered protein function of N-acetylgalactosamine 4-sulfatase at multiple points in the vacuolar network. Biochemistry 2002;41:4962-71.
16. Lee-Chen GJ, Lin SP, Ko MH, Chuang CK, Chen CP, Lee HH, Cheng SC, Shen CH, Tseng KL, Li CL. Identification and characterization of mutations underlying Sanfilippo syndrome type A (mucopolysaccharidosis type IIIA). Clin Genet 2002;61:192-7.
17. Tanaka A, Kimura M, Lan HT, Takaura N, Yamano T. Molecular analysis of the alpha-N-acetylglucosaminidase gene in seven Japanese patients from six unrelated families with mucopolysaccharidosis IIIB (Sanfilippo type B), including two novel mutations. J Hum Genet 2002;47:484-7.
18. Litjens T, Hopwood JJ. Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. Hum Mutat 2001;18:282-95.
19. Bunge S, Kleijer WJ, Tylki-Szymanska A, Steglich C, Beck M, Tomatsu S, Fukuda S, Poorthuis BJ, Czartoryska B, Orii T, Gal A. Identification of 31 novel mutations in the N-acetylgalactosamine-6-sulfatase gene reveals excessive allelic heterogeneity among patients with Morquio A syndrome. Hum Mutat 1997;10:223-32.
20. Lee-Chen GJ, Lin SP, Lin SZ, Chuang CK, Hsiao KT, Huang CF, Lien WC. Identification and characterisation of mutations underlying Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). J Med Genet 2002;39:E3.
21. Cervos-Navarro J, Goebel HH. Stoffwechselstörungen. In: Cervos-Navarro J, Ferzt R, eds. Klinische Neuropathologie. Thieme, Stuttgart 1989, pp150-207.
22. Dekaban AS, Constantopoulos G. Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain. Acta Neuropathol (Berl) 1977;39:1-7.
23. Koto A, Horwitz AL, Suzuki K, Tiffany CW, Suzuki K. The Morquio syndrome: neuropathology and biochemistry. Ann Neurol 1978;4:26-36.
24. Birkenmeier EH, Davisson MT, Beamer WG, Ganschow RE, Vogler CA, Gwynn B, Lyford KA, Maltais LM, Wawrzyniak CJ. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 1989;83:1258-66.
25. Passini MA, Lee EB, Heuer GG, Wolfe JH. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 2002;22:6437-46.
26. Walkley SU, Haskins ME, Shull RM. Alterations in neuron morphology in mucopolysaccharidosis type I. A Golgi study. Acta Neuropathol (Berl) 1988;75:611-20.
27. McKusick VA, Neufeld EF, Kelly TE. The mucopolysaccharide storage diseases. In: Stanbury JB, Wyngaarden JB, Frederickson DS, Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease, 5th ed. McGraw-Hill, New York 1983, 751. Cited by [84].
28. Watts RW, Spellacy E, Adams JH. Neuropathological and clinical correlations in Hurler disease. J Inher Metab Dis 1986;9:261-72.
29. Berry CL, Vogler C, Galvin NJ, Birkenmeier EH, Sly WS. Pathology of the ear in murine mucopolysaccharidosis type VII. Morphologic correlates of hearing loss. Lab Invest 1994;71:438-45.
30. Fuller M, Meikle PJ, Hopwood JJ. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I. Glycobiology 2004;14:443-50.
31. Wraith JE, Alani SM. Carpal tunnel syndrome in the mucopolysaccharidoses and related disorders. Arch Dis Child 1990;65:962-3.
32. Haddad FS, Jones DH, Vellodi A, Kane N, Pitt MC. Carpal tunnel syndrome in the mucopolysaccharidoses and mucolipidoses. J Bone Joint Surg Br 1997;79:576-82.
33. Van Meir N, De Smet L. Carpal tunnel syndrome in children. Acta Orthop Belg 2003;69:387-95.
34. Nelson J, Shields MD, Mulholland HC. Cardiovascular studies in the mucopolysaccharidoses. J Med Genet 1990;27:94-100.
35. Petitti N, Holder CA, Williams DW. Mucopolysaccharidosis III (Sanfilippo syndrome) type B: cranial imaging in two cases. J Comput Assist Tomogr 1997;21:897-9.
36. Berry HK. Screening for mucopolysaccharide disorders with the Berry spot test. Clin Biochem 1987;20:365-71.
37. de Jong JG, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 1992;38:803-7.
38. Mabe P, Valiente A, Soto V, Cornejo V, Raimann E. Evaluation of reliability for urine mucopolysaccharidosis screening by dimethylmethylene blue and Berry spot tests. Clin Chim Acta 2004;345:135-40.
39. Pennock CA. A review and selection of simple laboratory methods used for the study of glycosaminoglycan excretion and the diagnosis of the mucopolysaccharidoses. J Clin Pathol 1976;29:111-23.
40. Voznyi YV, Keulemans JL, van Diggelen OP. A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inherit Metab Dis 2001;24:675-80.
41. Parkinson EJ, Muller V, Hopwood JJ, Brooks DA. Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients. Mol Genet Metab 2004;81:58-64.
42. Dean CJ, Bockmann MR, Hopwood JJ, Brooks DA, Meikle PJ. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples. Clin Chem 2006;52:643-9.
43. Hochuli M, Wüthrich K, Steinmann B. Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses. NMR Biomed 2003;16:224-36.
44. Perkins KJ, Muller V, Weber B, Hopwood JJ. Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients. Mol Genet Metab 2001;73:306-12.
45. Nelson K, Melville EL, Meikle PJ, Ansons DS. Immortalisation of a mucopolysaccharidosis type IIIC fibroblast cell line via expression of SV40 T antigen. Cell Biol Int 2003;27:567-70.
46. Seyrantepe V, Tihy F, Pshezhetsky AV. The microcell-mediated transfer of human chromosome 8 restores the deficient N-acetylytransferase activity in skin fibroblasts of Mucopolysaccharidosis type IIIC patients. Hum Genet 2006;120:293-6.
47. Keulemans JL, Sinigerska I, Garritsen VH, Huijmans JG, Voznyi YV, van Diggelen OP, Kleijer WJ. Prenatal diagnosis of the Hunter syndrome and the introduction of a new fluorimetric enzyme assay. Prenat Diagn 2002;22:1016-21.
48. Zhang WM, Shi HP, Li BT, Zhao SM, Qi QW, Sun NH, Huang SZ. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type II (Hunter syndrome)] Zhonghua Er Ke Za Zhi 2006;44:644-7.
49. Braunlin E, Mackey-Bojack S, Panoskaltsis-Mortari A, Berry JM, McElmurry RT, Riddle M, Sun LY, Clarke LA, Tolar J, Blazar B. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome. Pediatr Res 2006;59:27-32.
50. Sato S, Maeda N, Watanabe H, Tano Y, Inoue Y, Shimomura Y, Tanaka A. Multiple iridociliary cysts in patients with mucopolysaccharidoses. Br J Ophthalmol 2002;86:933-4.
51. Ashworth JL, Biswas S, Wraith E, Lloyd IC. Mucopolysaccharidosis and the eye. Surv Ophthalmol 2006;51:1-17.
52. Lipson SJ. Dysplasia of the odontoid process in Morquio's syndrome causing quadriparesis. J Bone Joint Surg Am 1977;59:340-4.
53. Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, Muenzer J, Norato DY, Shapiro E, Thomas J, Viskochil D, Wraith JE. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab 2007;91:37-47.
54. Fuller M, Brooks DA, Evangelista M, Hein LK, Hopwood JJ, Meikle PJ. Prediction of neuropathology in mucopolysaccharidosis I patients. Mol Genet Metab 2005;84:18-24.
55. Allen JL. Treatment of respiratory system (not just lung!) Abnormalities in mucopolysaccharidosis I. J Pediatr 2004;144:561-2.
56. Shih SL, Lee YJ, Lin SP, Sheu CY, Blickman JG. Airway changes in children with mucopolysaccharidosis. Acta Radiol 2002;43:40-3.
57. Leighton SE, Papsin B, Vellodi A, Dinwiddie R, Lane R. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 2001;58:127-138.
58. Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, Okazaki S, Huff K, Cox GF, Swiedler SJ, Kakkis ED. A follow-up study of MPS I patients treated with Iaronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007;90:171-80.
59. Musharbash A. Carpal tunnel syndrome in a 28-month-old child. Pediatr Neurosurg 2002;37:32-4.
60. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995; 72: 263-7.
61. Young ID, Harper PS, Newcombe RG, Archer IM. A clinical and genetic study of Hunter's syndrome. 2. Differences between the mild and severe forms. J Med Genet 1982;19:408-11. Cited form Van der Knaap MS, Valk J. Mucopolysaccharidoses. In: Van der Knaap MS, Valk J, eds. Magnetic resonance of myelination and myelin disorders, 3rd ed. Springer, Heidelberg-New York-Wien 2005, pp 123-32.
62. Shapiro J, Strome M, Crocker AC. Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol 1985;94:458-61.
63. Orliaguet O, Pepin JL, Veale D, Kelkel E, Pinel N, Levy P. Hunter's syndrome and associated sleep apnoea cured by CPAP and surgery. Eur Respir J 1999;13:1195-7.
64. Davitt SM, Hatrick A, Sabharwal T, Pearce A, Gleeson M, Adam A. Tracheobronchial stent insertions in the management of major airway obstruction in a patient with Hunter syndrome (type-II mucopolysaccharidosis). Eur Radiol 2002;12:458-62.
65. Kettles DI, Sheppard M, Liebmann RD, Davidson C. Left ventricular aneurysm, aortic valve disease and coronary narrowing in a patient with Hunter's syndrome. Cardiovasc Pathol 2002;111:94-6.
66. van de Kamp JJ, Niermeijer MF, von Figura K, Giesberts MA. Genetic heterogeneity and clinical variability in the Sanfilippo syndrome (types A, B, and C). Clin Genet 1981;20:152-60.
67. Turki I, Kresse H, Scotto J, Tardieu M. Sanfilippo disease, type C: three cases in the same family. Neuropediatrics 1989;20:90-2.
68. Kurihara M, Kumagai K, Yagishita S. Sanfilippo syndrome type C: a clinicopathological autopsy study of a long-term survivor. Pediatr Neurol 1996;14:317-21.
69. Zafeiriou DI, Savvopoulou-Augoustidou PA, Sewell A, Papadopoulou F, Badouraki M, Vargiami E, Gombakis NP, Katzos GS. Serial magnetic resonance imaging findings in mucopolysaccharidosis IIIB (Sanfilippo's syndrome B). Brain Dev 2001;23:385-9.
70. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 1996;19:357-65.
71. Rigante D, Antuzzi D, Ricci R, Segni G. Cervical myelopathy in mucopolysaccharidosis type IV. Clin Neuropathol 1999;18:84-6.
72. Nelson J, Broadhead D, Mossman J. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part I: Clinical and biochemical findings. Clin Genet 1988;33:111-20.
73. Mikles M, Stanton RP. A review of Morquio syndrome. Am J Orthop 1997;26:533-40.
74. Vervoort R, Islam MR, Sly WS, Zabot MT, Kleijer WJ, Chabas A, Fensom A, Young EP, Liebaers I, Lissens W. Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII. Am J Hum Genet 1996;58:457-71.
75. Lee JE, Falk RE, Ng WG, Donnell GN. Beta-glucuronidase deficiency. A heterogeneous mucopolysaccharidosis. Am J Dis Child 1985;139:57-9.
76. Bernsen PL, Wevers RA, Gabreels FJ, Lamers KJ, Sonnen AE, Stekhoven JH. Phenotypic expression in mucopolysaccharidosis VII. J Neurol Neurosurg Psychiatry 1987;50:699-703.
77. Van Buggenhout GJ, Trijbels JM, Wevers R, Trommelen JC, Hamel BC, Brunner HG, Fryns JP. Metabolic studies in older mentally retarded patients: significance of metabolic testing and correlation with the clinical phenotype. Genet Couns 2001;12:1-21.
78. Seto T, Kono K, Morimoto K, Inoue Y, Shintaku H, Hattori H, Matsuoka O, Yamano T, Tanaka A. Brain magnetic resonance imaging in 23 patients with mucopolysaccharidoses and the effect of bone marrow transplantation. Ann Neurol 2001;50:79-92.
79. Grodd W, Krägeloh-Mann I. Stoffwechselstörungen im Kindesalter. In: Jansen O, Stephani U, eds. Fehlbildungen (RRN). Thieme, Stuttgart 2007, pp 114-81.
80. Murata R, Nakajima S, Tanaka A, Miyagi N, Matsuoka O, Kogame S, Inoue Y. MR imaging of the brain in patients with mucopolysaccharidosis. AJNR Am J Neuroradiol 1989;10:1165-70.
81. Barkovich AJ. Toxic and metabolic brain disorders. In: AJ Barkovich, ed. Pediatric Neuroimaging, 3rd ed. Lippincott Williams & Wilkins, Philadelphia/USA 2000, pp 71-156.
82. Patay Z. Metabolic disorders. In: P Tortori-Donati, A Rossi, eds. Pediatric Neuroradiology: Brain. Springer, Heidelberg-New York-Wien 2005, pp 543-721.
83. Kulkarni MV, Williams JC, Yeakley JW, Andrews JL, McArdle CB, Narayana PA, Howell RR, Jonas AJ. Magnetic resonance imaging in the diagnosis of the cranio-cervical manifestations of the mucopolysaccharidoses. Magn Reson Imaging 1987;5:317-23.
84. Taccone A, Tortori Donati P, Marzoli A, Dell'Acqua A, Gatti R, Leone D. Mucopolysaccharidosis: thickening of dura mater at the craniocervical junction and other CT/MRI findings. Pediatr Radiol 1993;23:349-52.
85. Barone R, Nigro F, Triulzi F, Musumeci S, Fiumara A, Pavone L. Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome). Neuropediatrics 1999;30:270-4.
86. Matheus MG, Castillo M, Smith JK, Armao D, Towle D, Muenzer J. Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 2004;46:666-72.
87. Takahashi Y, Sukegawa K, Aoki M, Ito A, Suzuki K, Sakaguchi H, Watanabe M, Isogai K, Mizuno S, Hoshi H, Kuwata K, Tomatsu S, Kato S, Ito T, Kondo N, Orii T. Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidoses by 1H-magnetic resonance spectroscopy before and after bone marrow transplantation. Pediatr Res 2001;49:349-55.
88. Gabrielli O, Polonara G, Regnicolo L, Petroni V, Scarabino T, Coppa GV, Salvolini U. Correlation between cerebral MRI abnormalities and mental retardation in patients with mucopolysaccharidosis. Am J Med Genet A 2004;125:224-31.
89. Barone R, Parano E, Trifiletti RR, Fiumara A, Pavone P. White matter changes mimicking a leukodystrophy in a patient with mucopolysaccharidosis: characterization by MRI. J Neurol Sci 2002;195:171-5.
90. Lee C, Dineen TE, Brack M, Kirsch JE, Runge VM. The mucopolysaccharidoses: characterization by cranial MR imaging. AJNR Am J Neuroradiol 1993;14:1285-92.
91. Ogawa T, Okudera T, Fukasawa H, Hashimoto M, Inugami A, Fujita H, Hatazawa J, Shimosegawa E, Noguchi K, Uemura K. Unusual widening of the Virchow-Robin spaces: MR appearance. AJNR Am J Neuroradiol 1995;16:1238-42.
92. Song CJ, Kim JH, Kier EL, Bronen RA. MR imaging and histologic features of subinsular bright spots on T2-weighted MR images: Virchow-Robin spaces of the extreme capsule and insular cortex. Radiology 2000;214:671-7.
93. Achiron A, Faibel M. Sandlike appearance of Virchow-Robin spaces in early multiple sclerosis: a novel neuroradiological marker. AJNR Am J Neuroradiol 2002;23:376-80.
94. Fanous R, Midia M. Perivascular spaces: normal and giant. Can J Neurol Sci 2007;34:5-10.
95. Hutchings M, Weller RO. Anatomical relationship of the pia mater to cerebral blood vessels in man. J Neurosurg 1986;65:316-25.
96. Pollock H, Hutchings M, Weller RO, Zhang ET. Perivascular spaces in the basal ganglia of the human brain: their relationship to lacunes. J Anat 1997;191:337-46.
97. Zhang ET, Inman CB, Weller RO. Interrelationships of the pia mater and the perivascular (Virchow-Robin) spaces in the human cerebrum. J Anat 1990;170:11-123.
98. Cheon JE, Kim IO, Hwang YS, Kim KJ, Wang KC, Cho BK, Chi JG, Kim CJ, Kim WS, Yeon KM. Leukodystrophy in children: a pictorial review of MR imaging features. Radiographics 2002;22:461-76.
99. Öztürk MH, Aydingöz Ü. Comparison of MR signal intensities of cerebral perivascular (Virchow-Robin) and subarachnoid spaces. J Comput Assist Tomogr 2002;26:902-4.
100. Kalimo H, Kaste M, Haltia M. Vascular diseases. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology 6th ed. Arnold, London 1997, pp 315-96.
101. Duvernoy HM. Cortical blood vessels of the human brain. In: Yasargil MG, ed. Microneurosurgery III A. Thieme, New York 1987, pp 338-45.
102. Stevens JM, Kendall BE, Crockard HA, Ransford A. The odontoid process in Morquio-Brailsford's disease. The effects of occipitocervical fusion. J Bone Joint Surg Br 1991;73:851-8.
103. Nelson J, Thomas PS. Clinical findings in 12 patients with MPS IV A (Morquio's disease). Further evidence for heterogeneity. Part III: Odontoid dysplasia. Clin Genet 1988;33:126-30.
104. Tamaki N, Kojima N, Tanimoto M, Suyama T, Matsumoto S. Myelopathy due to diffuse thickening of the cervical dura mater in Maroteaux-Lamy syndrome: report of a case. Neurosurgery 1987;21:416-9.
105. Young R, Kleinman G, Ojemann RG, Kolodny E, Davis K, Halperin J, Zalneraitis E, Delong GR. Compressive myelopathy in Maroteaux-Lamy syndrome: clinical and pathological findings. Ann Neurol 1980;8:336-40.
106. Wald SL, Schmidek HH. Compressive myelopathy associated with type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 1984;14:83-8.
107. Thorne JA, Javadpour M, Hughes DG, Wraith E, Cowie RA. Craniovertebral abnormalities in Type VI mucopolysaccharidosis (Maroteaux-Lamy syndrome). Neurosurgery 2001;48:849-52.
108. Boor R, Miebach E, Brühl K, Beck M. Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidoses. Neuropediatrics 2000;31:122-7.
109. Mut M, Cila A, Varli K, Akalan N. Multilevel myelopathy in Maroteaux-Lamy syndrome and review of the literature. Clin Neurol Neurosurg 2005;107:230-5.
110. Herskhovitz E, Young E, Rainer J, Hall CM, Lidchi V, Chong K, Vellodi A. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis 1999;22:50-62.
111. Cabrera-Salazar M, Novelli E, Barranger JA. Gene therapy for the lysosomal storage disorders. Curr Opin Mol Ther 2002;4:349-58.
112. Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004;6:481-506.
113. Fu H, Kang L, Jennings JS, Moy SS, Perez A, Dirosario J, McCarty DM, Muenzer J. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 2007;14:1065-77.
114. Beck M. New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy. Hum Genet 2007;121:1-22.
115. Sly WS, Vogler C. Brain-directed gene therapy for lysosomal storage disease: going well beyond the blood- brain barrier. Proc Natl Acad Sci USA 2002;99:5760-2.
116. Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004;62:1066-72.
117. Sly WS. Enzyme replacement therapy: from concept to clinical practice. Acta Pediatr Suppl 2002;91:71-8.
118. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-9.
119. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Phillips J, Doroshow R, Walot I, Hoft R, Neufeld EF. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-8.
120. Miebach E. Enzyme replacement therapy in mucopolysaccharidosis type I. Acta Pediatr 2005;94:58-60, suppl.
121. Thomas JA, Jacobs S, Kierstein J, Van Hove J. Outcome after three years of Iaronidase enzyme replacement therapy in a patient with Hurler syndrome. J Inherit Metab Dis 2006;29:762.
122. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, Kaplan P, Simon J, Butensky E, Hopwood JJ. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr 2004;144:574-80.
123. Beck M. Galsulfase: Enzyme-replacement therapy for mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome). Therapy 2006;3:9-17.
124. Church H, Tylee K, Cooper A, Thornley M, Mercer J, Wraith E, Carr T, O'Meara A, Wynn RF. Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant 2007;39:207-10.
125. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ, O'Meara A, Cornu G, Souillet G, Frappaz D, Blanche S, Fischer A, for the European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for lysosomal storage diseases. Lancet 1995;345:1398-402.
126. Cabrera-Salazar M, Novelli E, Barranger JA. Gene therapy for the lysosomal storage disorders. Curr Opin Mol Ther 2002;4:349-58.
127. Grewal SS, Krivit W, Defor TE, Shapiro EG, Orchard PJ, Abel SL, Lockman LA, Ziegler RS, Dusenbery KE, Peters C. Outcome of second hematopoietic cell transplantation in Hurler syndrome. Bone Marrow Transplant 2002;29:491-6.
128. Koç ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002;30:215-22.
129. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 2005;7:143-6.
130. Käsmann-Kellner B, Weindler J, Pfau B, Ruprecht KW. Ocular changes in mucopolysaccharidosis IV A (Morquio A syndrome) and longterm results of perforating keratoplasty. Ophthalmologica 1999;213:200-5.
131. Bergwerk KE, Falk RE, Glasgow BJ, Rabinowitz YS. Corneal transplantation in a patient with mucopolysaccharidosis type VII (Sly disease). Ophthalmic Genet 2000;21:17-20.
132. Yoskovitch A, Tewfik TL, Brouillette RT, Schloss MD, Der Kaloustian VM. Acute airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 1998;44:273-8.
133. Shinhar SY, Zablocki H, Madgy DN. Airway management in mucopolysaccharidosis storage disorders. Arch Otolaryngol Head Neck Surg 2004;130:233-7.
134. Khan FA, Khan FH. Use of the laryngeal mask airway in mucopolysaccharidosis. Paediatr Anaesth 2002;12:465-8.
135. Bhattacharya K, Gibson SC, Pathi VL. Mitral valve replacement for mitral stenosis secondary to Hunter's syndrome. Ann Thorac Surg 2005;80:1911-2.
136. Hachida M, Nonoyama M, Bonkohara Y, Hanayama N, Koyanagi H. Combined aortic and mitral valve replacement in an adult with mucopolysaccharidosis (Maroteaux-Lamy syndrome). Heart Vessels 1996;11:215-7.
137. Van Heest AE, House J, Krivit W, Walker K. Surgical treatment of carpal tunnel syndrome and trigger digits in children with mucopolysaccharide storage disorders. J Hand Surg [Am] 1998;23:236-43.
138. Ashraf J, Crockard HA, Ransford AO, Stevens JM. Transoral decompression and posterior stabilisation in Morquio's disease. Arch Dis Child 1991;66:1318-21.
139. Khan SA, Sehat K, Calthorpe D. Cervical cord decompression in an elderly patient with Hurler's syndrome: a case report. Spine 2003;28:E313-5.
140. Vougioukas VI, Berlis A, Kopp MV, Korinthenberg R, Spreer J, van Velthoven V. Neurosurgical interventions in children with Maroteaux-Lamy syndrome. Case report and review of the literature. Pediatr Neurosurg 2001;35:35-8.
141. Ebara S, Kinoshita T, Yuzawa Y, Takahashi J, Nakamura I, Hirabayashi H, Uozumi R, Kimura M, Takaoka K. A case of mucopolysaccharidosis IV with lower leg paresis due to thoraco-lumbar kyphoscoliosis. J Clin Neurosci 2003;10:358-61.